secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001437749-24-006099
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M
--------------------------------------------------------------------------------

- Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
- GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.
- Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.
- Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.
- Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/0001437749-24-006099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/pbyi20240227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-006099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer